| Previous Close | 7.34 |
| Open | 7.38 |
| Bid | 6.20 x 600 |
| Ask | 7.78 x 900 |
| Day's Range | 7.12 - 7.39 |
| 52 Week Range | 5.90 - 25.17 |
| Volume | 239,911 |
| Avg. Volume | 859,268 |
| Market Cap | 212.18M |
| Beta | 2.32 |
| PE Ratio (TTM) | -2.56 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Capital Cube•10 days ago
ETFs with exposure to NewLink Genetics Corp. : July 12, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NewLink Genetics Corp. Here are 5 ETFs with the largest exposure to NLNK-US. Comparing the performance and risk of NewLink Genetics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Motley Fool•last month
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
- Motley Fool•last month
A Surprising Disappointment Derails NewLink Genetics -- What's Next?
Roche Holdings has decided to walk away from co-developing NewLink Genetics IDO-inhibitor, GDC-0919.
